Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
RICHMOND, Calif., April 30, 2018 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2018 after the close of trading on Monday, May 7, 2018. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers, using Conference ID: 13581989. A live webcast of the event will be available in the “Investors” section of the company’s website at www.eksobionics.com, or by clicking here.
A replay of the call will be available for two weeks by dialing (877) 660-6853 for domestic callers or (201) 612-7415 for international callers, using Conference ID: 13581989. The webcast will also be available on the company’s website for one month following the completion of the call.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Media Contact:
Chantal Beaudry
212-867-1762
[email protected]
Investor Contact:
David Carey
212-867-1768
[email protected]
